Skip to main content
Advertisement
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
    • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Cardiovascular Case Series
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Minneapolis City Hospital
      • Pitié-Salpêtrière Hospital
      • Tufts Medical Center
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
    • On My Mind
    • Podcast Archive
      • → Circulation on the Run, FIT Edition
    • → Subscribe to Circulation on the Run
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
    • Scientific Sessions 2017
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Cardiovascular Genetics
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Cardiovascular Case Series
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
    • Scientific Sessions 2017
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Cardiovascular Genetics
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association

Search for author "Ron Simon"

  • Modify Search
  • Create Alert
  • Save Search

12 Results

Type a term to search within all articles in this journal: e.g., stem cell
Content Type
Select types of content to include in the results.
Citation
Citation-specific search information
e.g., 2009
e.g., 20
e.g., 3
e.g., 29
e.g., 10.9999/123XYZ456
Authors, Keywords
Search for specific authors and/or words and phrases.
e.g., Smith, JS
e.g., Smith, JS
Type any phrase that appears in the article title
Type any phrase that appears within article title or abstract
Type any phrase that appears within article body, title or abstract
e.g., Smith, JS
Book publisher name
Limit Results
Limit search results by date
e.g., 07/24/2017
e.g., 07/24/2017
Format Results
  • You have accessRestricted access
    Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated Mechanism
    Philberta Y. Leung, Susan L. Stevens, Amy E.B. Packard, Nikola S. Lessov, Tao Yang, Valerie K. Conrad, Noortje N.A.M. van den Dungen, Roger P. Simon and Mary P. Stenzel-Poore
    Stroke. 2012;43:1383-1389, originally published April 23, 2012
    https://doi.org/10.1161/STROKEAHA.111.641522
    Download PDF
  • You have access
    Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated Mechanism
    Philberta Y. Leung, Susan L. Stevens, Amy E.B. Packard, Nikola S. Lessov, Tao Yang, Valerie K. Conrad, Noortje N.A.M. van den Dungen, Roger P. Simon, Mary P. Stenzel-Poore
    Stroke May 2012, 43 (5) 1383-1389; DOI: https://doi.org/10.1161/STROKEAHA.111.641522
    Figure 1.
    Figure 1.
    Gardiquimod (GDQ) preconditioning reduces ischemic injury. A, C57Bl/6 mice were preconditio...
    Show More
    Gardiquimod (GDQ) preconditioning reduces ischemic injury. A, C57Bl/6 mice were preconditioned with escalating doses of GDQ (N=8; 10, 20, or 40 μg per mouse, subcutaneous) or saline (N=5) 72 hours before 60 minutes of middle cerebral artery occulusion (MCAO). Infarct size was determined 24 hours after MCAO. B, C57Bl/6 mice were pretreated with GDQ (N=8; 20 μg/mouse, subcutaneous) or saline (n=6) 72 hours before MCAO. Infarct size was determined 72 hours after MCAO. C, C57Bl/6 mice were pretreated with GDQ (N=5–6; 20 μg/mouse, subcutaneous) or saline (n=6) at various times before MCAO. Infarct size was determined 24 hours after MCAO. Two-way analysis of variance (ANOVA), Bonferroni post hoc, *P<0.01, **P<0.01, ***P<0.001 vs saline controls. D and E, C57BL/6 mice were treated with GDQ (N=5; 40 μg/mouse, subcutaneous) or saline (N=6) 72 hours before MCAO (60 minutes). Mice were then examined using the (D) neurological score (focal and general) and (E) corner test to determine neurological and sensorimotor deficits 24 hours after MCAO. Student t test: *P<0.01, **P<0.01, ***P<0.001 vs saline controls.
    Show Less
  • You have access
    Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated Mechanism
    Philberta Y. Leung, Susan L. Stevens, Amy E.B. Packard, Nikola S. Lessov, Tao Yang, Valerie K. Conrad, Noortje N.A.M. van den Dungen, Roger P. Simon, Mary P. Stenzel-Poore
    Stroke May 2012, 43 (5) 1383-1389; DOI: https://doi.org/10.1161/STROKEAHA.111.641522
    Figure 2.
    Figure 2.
    Gardiquimod (GDQ)-induced neuroprotection is mediated through Toll-like receptor (TLR) 7. TLR7+/+...
    Show More
    Gardiquimod (GDQ)-induced neuroprotection is mediated through Toll-like receptor (TLR) 7. TLR7+/+ (N=7) or TLR7−/− (N=5–7) mice were preconditioned with GDQ (40 μg/mouse, subcutaneous) or saline 72 hours before middle cerebral artery occlusion (MCAO; 45 minutes). Infarct size was determined 24 hours after MCAO. Two-way analysis of variance (ANOVA), Bonferroni post hoc, **P<0.01 vs saline control for respective genotype.
    Show Less
  • You have access
    Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated Mechanism
    Philberta Y. Leung, Susan L. Stevens, Amy E.B. Packard, Nikola S. Lessov, Tao Yang, Valerie K. Conrad, Noortje N.A.M. van den Dungen, Roger P. Simon, Mary P. Stenzel-Poore
    Stroke May 2012, 43 (5) 1383-1389; DOI: https://doi.org/10.1161/STROKEAHA.111.641522
    View table
    Table.
    Interferon-Associated Genes in the Brains of Gardiquimod-Preconditioned Animals After Middle Cerebral Artery Occlusion (24 Hours)Show More
    Interferon-Associated Genes in the Brains of Gardiquimod-Preconditioned Animals After Middle Cerebral Artery Occlusion (24 Hours)Show Less
  • You have access
    Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated Mechanism
    Philberta Y. Leung, Susan L. Stevens, Amy E.B. Packard, Nikola S. Lessov, Tao Yang, Valerie K. Conrad, Noortje N.A.M. van den Dungen, Roger P. Simon, Mary P. Stenzel-Poore
    Stroke May 2012, 43 (5) 1383-1389; DOI: https://doi.org/10.1161/STROKEAHA.111.641522
    Figure 3.
    Figure 3.
    Tumor necrosis factor (TNF) is not required for Toll-like receptor (TLR)7-induced neuroprotection. A...
    Show More
    Tumor necrosis factor (TNF) is not required for Toll-like receptor (TLR)7-induced neuroprotection. A, C57Bl/6 mice were injected with either Gardiquimod (GDQ; 40 μg/mouse, subcutaneous), lipopolysaccharide (LPS; 20 μg/mouse, subcutaneous), or saline. Blood was collected at various time points after injection and serum levels of TNF were determined via enzyme-linked immunosorbent assay (ELISA). N.D.=not detected (N=4 – 6). B, TNF−/− (N=6 – 8) and TNF+/+ mice (N=7) were injected with GDQ (40 μg/mouse, subcutaneous) or saline 72 hours before middle cerebral artery occlusion (MCAO; 50 minutes). Infarct size was determined 24 hours after MCAO. Two-way analysis of variance (ANOVA), Bonferroni post hoc: *P<0.05 vs saline controls.
    Show Less
  • You have access
    Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated Mechanism
    Philberta Y. Leung, Susan L. Stevens, Amy E.B. Packard, Nikola S. Lessov, Tao Yang, Valerie K. Conrad, Noortje N.A.M. van den Dungen, Roger P. Simon, Mary P. Stenzel-Poore
    Stroke May 2012, 43 (5) 1383-1389; DOI: https://doi.org/10.1161/STROKEAHA.111.641522
    Figure 4.
    Figure 4.
    Gardiquimod (GDQ)-preconditioning induces IFNα and requires IRF7 for neuroprotection. A, C5...
    Show More
    Gardiquimod (GDQ)-preconditioning induces IFNα and requires IRF7 for neuroprotection. A, C57Bl/6 mice were injected with GDQ (40 μg/mouse, subcutaneous), unmethylated cytosine-phosphate-guanine rich oligonucleotide (40 μg/mouse, subcutaneous), lipopolysaccharide (LPS; 20 μg/mouse, subcutaneous), or saline. Blood was collected at indicated times and serum interferon (IFN)α levels were measured (N=4–10). Two-way analysis of variance (ANOVA), Bonferroni post hoc: *P<0.05, ***P<0.001 vs saline controls. B, IRF7−/− and IRF7+/+ mice were injected with 40 μg GDQ or saline. Blood was collected at 2 hours and serum IFNα was measured (N=3 – 8). One-way ANOVA, Bonferroni post hoc: *P<0.05 vs saline controls. C, IRF7+/+ (N=8–9) or IRF7−/− mice (N=7–9) were preconditioned with GDQ (40 μg/mouse, subcutaneous) or saline 72 hours before MCAO (45 minutes). Infarct size was determined 24 hours after middle cerebral artery occlusion (MCAO). Two-way ANOVA, Bonferroni post hoc: **P<0.01 vs saline controls.
    Show Less
  • You have access
    Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated Mechanism
    Philberta Y. Leung, Susan L. Stevens, Amy E.B. Packard, Nikola S. Lessov, Tao Yang, Valerie K. Conrad, Noortje N.A.M. van den Dungen, Roger P. Simon, Mary P. Stenzel-Poore
    Stroke May 2012, 43 (5) 1383-1389; DOI: https://doi.org/10.1161/STROKEAHA.111.641522
    Figure 5.
    Figure 5.
    Type I interferon receptor (IFNAR) signaling is required for TLR7-mediated neuroprotection. IFNAR+/+...
    Show More
    Type I interferon receptor (IFNAR) signaling is required for TLR7-mediated neuroprotection. IFNAR+/+ and IFNAR−/− mice were injected with Gardiquimod (GDQ; N=6 – 8), unmethylated cytosine-phosphate-guanine rich oligonucleotide (N=8–11), lipopolysaccharide (LPS; N=8–11), or saline (N=6 – 9) 72 hours before middle cerebral artery occlusion (MCAO; 45 minutes). Infarct size was determined 24 hours after MCAO. The data are presented as percent damage normalized to saline plus MCAO. Two-way analysis of variance (ANOVA), Bonferroni post hoc: ***P<0.001 vs saline control for respective genotype; #P<0.05 vs IFNAR+/+ for respective treatment.
    Show Less
  • You have accessRestricted access
    Extracellular Zinc Protects Against Acidosis-Induced Injury of Cells Expressing Ca2+-Permeable Acid-Sensing Ion Channels
    Jessica G. Hey, Xiang-Ping Chu, Joshua Seeds, Roger P. Simon and Zhi-Gang Xiong
    Stroke. 2007;38:670-673, originally published January 29, 2007
    https://doi.org/10.1161/01.STR.0000251443.68897.99
    Download PDF
  • You have access
    Extracellular Zinc Protects Against Acidosis-Induced Injury of Cells Expressing Ca2+-Permeable Acid-Sensing Ion Channels
    Jessica G. Hey, Xiang-Ping Chu, Joshua Seeds, Roger P. Simon, Zhi-Gang Xiong
    Stroke February 2007, 38 (2) 670-673; DOI: https://doi.org/10.1161/01.STR.0000251443.68897.99
    Figure 1. Lowering extracellular pH activates ASIC1a currents in HEK293 cells and these currents are potentiated by reducing Zn2+ concentrations. A, R...Show More
    Figure 1. Lowering extracellular pH activates ASIC1a currents in HEK293 cells and these currents are potentiated by reducing Zn2+ concentrations. A, Representative current traces demonstrating the activation of ASIC1a-like current in HEK293 cells. The current is largely inhibited by PcTX venom (150 ng/mL), a specific blocker for homomeric ASIC1a channels. Reducing the concentration of Zn2+ by perfusion with 10 μmol/L TPEN dramatically increased the amplitude of the ASIC current. In contrast, perfusion of the cells with 10 μmol/L ZnCl2 slightly inhibited the ASIC current. B, Summary bar graph demonstrating the effect of changing the concentration of Zn2+ on ASIC current in HEK293 cells. n=5. **P<0.01 compared with control group.Show Less
  • You have access
    Extracellular Zinc Protects Against Acidosis-Induced Injury of Cells Expressing Ca2+-Permeable Acid-Sensing Ion Channels
    Jessica G. Hey, Xiang-Ping Chu, Joshua Seeds, Roger P. Simon, Zhi-Gang Xiong
    Stroke February 2007, 38 (2) 670-673; DOI: https://doi.org/10.1161/01.STR.0000251443.68897.99
    Figure 2. Acid incubation induces injury of HEK293 cells. A, Representative black and white images showing the acid-induced injury of HEK293 cells. Ce...Show More
    Figure 2. Acid incubation induces injury of HEK293 cells. A, Representative black and white images showing the acid-induced injury of HEK293 cells. Cells were incubated with extracellular solutions with pH buffered at either 7.4 or 5.5 for 3 hours before switching back to neurobasal medium. Photographs were taken 24 hours after the acid incubation. B, Bar graph summarizing time-dependent injury of HEK293 cells as indicated by increase in LDH release, after the acid incubation. LDH release at various time points has been normalized to the maximal releasable amount obtained by incubating cells with 1% Triton X-100 for 15 minutes. *P<0.05 and **P<0.01 compared with pH 7.4 treated group at the same time points.Show Less

Pages

  • 1
  • 2
  • Next Page
Back to top

Selected Facets

Selected Facets

  • Neuroprotectors (Article Type)

Publication Date

Publication date

  • 2008-2012 7
  • 2003-2007 5

Subject

Subject

  • Acute Cerebral Infarction 7
  • Cerebrovascular disease/stroke 7
  • Neuroprotectors 12

Content Type

Resource Type

  • Articles 2
  • Tables & Figures 10
Advertisement
Advertisement

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2017 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured